Study S001592

A Multi-center, Single-dose, Parallel-group, Open-label Study to Evaluate the Pharmacokinetics of HRS9531 Injection in Participants With Mild, Moderate, and Normal Hepatic Function

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07540754
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: RECRUITING
Enrollment: 24
Start: 2026-05-26
Primary completion: 2027-01
Lead sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions: Diabetes Mellitus; Weight Loss
Interventions: DRUG:HRS9531 Injection
Results posted: FALSE
Individual participant data sharing: UNDECIDED

Registered primary outcomes

Maximum concentration (Cmax) [Post-dose from Day 1 to Day 29.]
The area under the concentration-time curve to the last measurable concentration (AUClast) [Post-dose from Day 1 to Day 29.]
The area under the concentration-time curve extrapolated to infinity (AUCinf) [Post-dose from Day 1 to Day 29.]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.